Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) have been assigned a consensus recommendation of “Hold” from the six analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $17.50.

A number of analysts have issued reports on TRDA shares. Roth Mkm set a $10.00 price target on Entrada Therapeutics in a research note on Friday, May 8th. Cantor Fitzgerald began coverage on Entrada Therapeutics in a research note on Wednesday, April 1st. They set an “overweight” rating for the company. Oppenheimer lifted their price objective on Entrada Therapeutics from $21.00 to $23.00 and gave the company an “outperform” rating in a research note on Monday, April 6th. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Finally, Wall Street Zen cut Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th.

Entrada Therapeutics Stock Performance

Shares of NASDAQ:TRDA opened at $7.09 on Monday. The stock’s 50-day moving average price is $9.15 and its two-hundred day moving average price is $10.59. Entrada Therapeutics has a 12-month low of $4.93 and a 12-month high of $16.45. The firm has a market cap of $275.23 million, a price-to-earnings ratio of -1.78 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.11. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%.The firm had revenue of $0.88 million for the quarter, compared to analyst estimates of $2.92 million. As a group, research analysts forecast that Entrada Therapeutics will post -4.12 earnings per share for the current fiscal year.

Insider Transactions at Entrada Therapeutics

In other news, Director Bernhardt G. Zeiher bought 5,000 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $5.86 per share, for a total transaction of $29,300.00. Following the acquisition, the director owned 5,000 shares of the company’s stock, valued at $29,300. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Nathan J. Dowden sold 15,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $15.33, for a total value of $229,950.00. Following the sale, the chief operating officer owned 198,588 shares of the company’s stock, valued at $3,044,354.04. The trade was a 7.02% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 43,407 shares of company stock worth $661,034 over the last 90 days. Company insiders own 9.49% of the company’s stock.

Institutional Trading of Entrada Therapeutics

A number of institutional investors have recently modified their holdings of TRDA. Millennium Management LLC grew its holdings in shares of Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after purchasing an additional 666,287 shares during the period. Citadel Advisors LLC lifted its position in Entrada Therapeutics by 234.5% during the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock worth $1,947,000 after acquiring an additional 235,384 shares in the last quarter. Baker BROS. Advisors LP lifted its position in Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after acquiring an additional 206,911 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in Entrada Therapeutics by 115.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock worth $1,670,000 after acquiring an additional 154,143 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Entrada Therapeutics by 4,767.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 148,212 shares of the company’s stock worth $860,000 after acquiring an additional 145,167 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.